Cleara Biotech Raises $2.5 Million in Seed Financing to Advance FOXO4-Therapeutics Pipeline for Treating Cancer and Chronic Diseases
Summary
Furthermore, they show favorable pharmacokinetics and tissue distribution in mice, with an MTD that is well above their efficacious dose.Additionally, Cleara has appointed Dr. Angelos Stergiou, New York-based SELLAS Life Sciences President and Chief Executive Officer, as its Board of Directors Chairman. Dr. Stergiou is a preeminent leader in the biotechnology industry with more than 20 years of experience in immuno-oncology, drug development and health economics, as well as deep expertise in finance and corporate governance.As Clearas vision is to develop novel, highly innovative approaches to combat life-threatening diseases, we look forward to further building the Companys pipeline and advancing our preclinical studies, said Dr. Peter de Keizer, Managing Director and Scientific Founder, Cleara. At the same time, Dr. Stergious deep expertise in cancer drug development and impressive track record of building companies will be invaluable to use as we scale our preclinical and regulatory efforts in the U.S. and EU to enter the clinic by 2024.Clearas novel FOXO4-based treatment approach, which harnesses the unique attributes of utilizing biomarkers and ability to eliminate biomarker-positive scarred cells, specific subsets of senescence, has the potential to be a disruptive treatment paradigm for many high-unmet-need cancer patient populations, added Dr. Stergiou. Clearas expertise lies in understanding the molecular and biological pathways that underlie these pathological phenotypes to exploit their weak spots for safe and selective clearance. Clearas lead program is designed to generate disruptive, innovative and proprietary technology against scarred cellular senescence against late-stage cancer and chronic diseases.